Sarcoma
MONDO:0005089A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.
Also known as: mesenchymal tumor, malignant, sarcoma, sarcoma of soft tissue and bone, sarcoma of the soft tissue and bone, sarcoma, malignant, tumor of soft tissue and skeleton, tumour of soft tissue and skeleton
3676 clinical trials for this condition and its sub-types, 493 tagged with Sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Sarcoma
-
Soft tissue sarcoma 296 trials · 645 incl. sub-types
46 sub-types
- Rhabdomyosarcoma 99 trials · 113 incl. sub-types Sub-types →
- Liposarcoma 58 trials · 83 incl. sub-types Sub-types →
- Angiosarcoma 37 trials · 82 incl. sub-types Sub-types →
- Rhabdoid tumor 63 trials · 75 incl. sub-types Sub-types →
- Central nervous system sarcoma 2 trials · 74 incl. sub-types Sub-types →
- Leiomyosarcoma 62 trials · 72 incl. sub-types Sub-types →
- Synovial sarcoma 53 trials Sub-types →
- Undifferentiated pleomorphic sarcoma 48 trials Sub-types →
- Desmoplastic small round cell tumor 26 trials
- Fibrosarcoma 9 trials · 21 incl. sub-types Sub-types →
- Myxofibrosarcoma 21 trials
- Alveolar soft part sarcoma 20 trials Sub-types →
- Epithelioid sarcoma 20 trials Sub-types →
- Retroperitoneal sarcoma 17 trials Sub-types →
- Clear cell sarcoma 14 trials · 16 incl. sub-types Sub-types →
- Liver sarcoma 1 trial · 10 incl. sub-types Sub-types →
- Skin sarcoma 1 trial · 9 incl. sub-types Sub-types →
- SMARCA4-deficient sarcoma of thorax 8 trials
- Kidney sarcoma 0 trials · 8 incl. sub-types Sub-types →
- Extraskeletal myxoid chondrosarcoma 7 trials Sub-types →
- Intimal sarcoma 4 trials
- Breast sarcoma 2 trials · 3 incl. sub-types Sub-types →
- Extraskeletal Ewing sarcoma 3 trials
- Undifferentiated round cell sarcoma 3 trials
- Extraosseous osteosarcoma 2 trials Sub-types →
- Ovarian sarcoma 0 trials · 2 incl. sub-types Sub-types →
- Heart sarcoma 1 trial Sub-types →
- Small intestinal sarcoma 0 trials · 1 incl. sub-types Sub-types →
- Testis sarcoma 0 trials · 1 incl. sub-types Sub-types →
- Anus sarcoma 0 trials Sub-types →
- Bladder sarcoma 0 trials
- Esophagus sarcoma 0 trials Sub-types →
- Gallbladder sarcoma 0 trials Sub-types →
- Laryngeal sarcoma 0 trials Sub-types →
- Lung sarcoma 0 trials Sub-types →
- Mediastinum sarcoma 0 trials Sub-types →
- Myxosarcoma 0 trials
- Pancreas sarcoma 0 trials
- Paranasal sinus sarcoma 0 trials
- Penile sarcoma 0 trials
- Prostate sarcoma 0 trials Sub-types →
- Stromal sarcoma 0 trials Sub-types →
- Thyroid sarcoma 0 trials Sub-types →
- Trachea sarcoma 0 trials
- Vagina sarcoma 0 trials Sub-types →
- Vulva sarcoma 0 trials Sub-types →
-
Osteosarcoma 169 trials · 173 incl. sub-types
6 sub-types
- Localized osteosarcoma 13 trials
- Bone osteosarcoma 8 trials Sub-types →
- Pediatric osteosarcoma 8 trials Sub-types →
- Extraosseous osteosarcoma 2 trials Sub-types →
- Low grade central osteosarcoma 0 trials
- Multifocal osteogenic sarcoma 0 trials Sub-types →
-
Ewing sarcoma 124 trials · 125 incl. sub-types
2 sub-types
- Ewing sarcoma of bone 5 trials
- Extraskeletal Ewing sarcoma 3 trials
-
Bone sarcoma 41 trials · 108 incl. sub-types
13 sub-types
- Undifferentiated pleomorphic sarcoma 48 trials Sub-types →
- Dedifferentiated chondrosarcoma 9 trials
- Bone giant cell tumor 7 trials · 8 incl. sub-types Sub-types →
- Bone osteosarcoma 8 trials Sub-types →
- Ewing sarcoma of bone 5 trials
- Undifferentiated high grade pleomorphic sarcoma of bone 4 trials
- Clear cell chondrosarcoma 3 trials
- Malignancy in giant cell tumor of bone 1 trial
- Bone angiosarcoma 0 trials
- Bone fibrosarcoma 0 trials
- Bone leiomyosarcoma 0 trials
- Liposarcoma of bone 0 trials
- Periosteal chondrosarcoma 0 trials
-
Dendritic cell sarcoma 0 trials · 53 incl. sub-types
3 sub-types
- Interdigitating dendritic cell sarcoma 53 trials
- Follicular dendritic cell sarcoma 2 trials
- Langerhans cell sarcoma 0 trials
-
Chondrosarcoma 39 trials · 44 incl. sub-types
4 sub-types
- Bone chondrosarcoma 1 trial · 10 incl. sub-types Sub-types →
- Mesenchymal chondrosarcoma 4 trials Sub-types →
- Myxoid chondrosarcoma 2 trials Sub-types →
- Localized chondrosarcoma 0 trials
-
Small cell sarcoma 0 trials · 37 incl. sub-types
6 sub-types
- Desmoplastic small round cell tumor 26 trials
- EWSR1-negative small round cell tumor 0 trials · 5 incl. sub-types Sub-types →
- Mesenchymal chondrosarcoma 4 trials Sub-types →
- Round cell sarcoma with EWSR1-non-ETS fusion 2 trials Sub-types →
- Sarcoma with BCOR genetic alterations 1 trial · 2 incl. sub-types Sub-types →
- Small cell osteogenic sarcoma 0 trials
-
Myeloid sarcoma 27 trials
1 sub-type
- Granulocytic sarcoma 0 trials
-
Uterine corpus sarcoma 12 trials · 19 incl. sub-types
3 sub-types
- Leiomyosarcoma of the corpus uteri 9 trials Sub-types →
- Uterine corpus endometrial stromal sarcoma 0 trials
- Uterine corpus rhabdomyosarcoma 0 trials
-
Spindle cell sarcoma 6 trials · 13 incl. sub-types
4 sub-types
- Intimal sarcoma 4 trials
- Spindle cell rhabdomyosarcoma 3 trials Sub-types →
- Spindle cell liposarcoma 0 trials
- Spindle cell synovial sarcoma 0 trials
-
Endometrioid stromal sarcoma 2 trials
3 sub-types
-
Ectomesenchymoma 1 trial
-
Giant cell tumor of soft tissue 1 trial
-
Sarcomatosis 1 trial
1 sub-type
- Sarcomatosis of the meninges 0 trials
-
Colon sarcoma 0 trials
2 sub-types
- Colon Kaposi sarcoma 0 trials
- Colon leiomyosarcoma 0 trials
-
Lymphangiosarcoma 0 trials
1 sub-type
- Skin lymphangiosarcoma 0 trials
-
Mast cell sarcoma 0 trials
-
Orbit sarcoma 0 trials
1 sub-type
- Orbit rhabdomyosarcoma 0 trials Sub-types →
-
Rectum sarcoma 0 trials
4 sub-types
- Anus sarcoma 0 trials Sub-types →
- Rectum Kaposi sarcoma 0 trials
- Rectum leiomyosarcoma 0 trials Sub-types →
- Rectum rhabdomyosarcoma 0 trials Sub-types →
-
Reticulum cell sarcoma 0 trials
-
Sarcoma G1 0 trials
-
Sarcoma of cervix uteri 0 trials
5 sub-types
Most studied deeper sub-types
-
Can a Blood-Flow-Blocking drug stall a rare sarcoma?
Disease control CompletedResearchers are testing sorafenib, a drug that blocks enzymes tumors need to grow and cuts off their blood supply, in people with angiosarcoma that is locally advanced, has spread, or cannot be removed by surgery. The trial enrolls about 88 participants and measures how many rema…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a dual immune antibody plus radiation shrink metastatic sarcoma?
Disease control CompletedResearchers are testing a combination of the experimental antibody MEDI5752 and stereotactic body radiotherapy in people with metastatic soft tissue sarcoma that has spread to the lungs. MEDI5752 targets two immune checkpoints, PD-1 and CTLA-4, and the radiation is aimed at one l…
Phase 1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can radiation turn tumors into targets for immunotherapy?
Disease control CompletedThis trial tests whether combining the immunotherapy drug atezolizumab with precise, high-dose radiation (SABR) can better control metastatic cancers, including colorectal, lung, kidney, and sarcoma. The idea is that radiation may make tumors more visible to the immune system, wh…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Immune cell boost shows promise against childhood cancers
Disease control CompletedThis early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase 1/2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Marine-Derived drug slow advanced soft tissue sarcoma?
Disease control CompletedThis phase III trial compares the chemotherapy drug trabectedin (Yondelis) with best supportive care in people with advanced soft tissue sarcoma, a rare cancer of the connective tissues. The goal is to see if trabectedin can delay tumor growth and improve outcomes compared to sup…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
Disease control CompletedThis pilot trial is investigating whether giving two immunotherapy drugs, nivolumab and ipilimumab, along with radiation therapy before surgery can safely help treat soft tissue sarcoma. The study enrolls adults with resectable, intermediate-to-high grade sarcomas larger than 5 c…
Early phase 1 • Sponsor: University of Rochester • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for kids with rare abdominal cancer: drug combo tested
Disease control CompletedThis study tested a drug called ramucirumab, given with standard chemotherapy, for children and young adults with a rare cancer called desmoplastic small round cell tumor (DSRCT) that had come back or not responded to treatment. The goal was to see if the combination could slow t…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shrinks tumors in patients with rare gene mutation
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase 1/2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Vitamin c boosts radiation for sarcoma? early trial shows promise
Disease control CompletedThis study tested whether giving high-dose vitamin C (ascorbate) alongside radiation therapy before surgery is safe and effective for people with advanced soft tissue sarcoma. 25 participants received vitamin C infusions three times a week during radiation. The goal was to see if…
Phase 1/2 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedThis study tested whether taking anlotinib pills after initial chemotherapy can help keep advanced soft tissue sarcoma from growing. 49 adults with certain types of sarcoma took anlotinib daily. The goal was to see how long the cancer stayed stable and to check safety. Anlotinib …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to shrink Hard-to-Treat sarcomas
Disease control CompletedThis phase 2 trial tests a combination of two drugs—chidamide and toripalimab—in people with advanced soft-tissue sarcoma that has not responded to standard treatments. Chidamide is a pill that may help the immune system recognize cancer cells, while toripalimab is an immunothera…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Phase 2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental t cell therapy targets sarcoma in small early trial
Disease control CompletedThis early-phase trial tested a personalized cell therapy for people with advanced bone or soft tissue sarcoma that had stopped responding to standard treatment. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells carrying a speci…
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo shows promise for rare sarcoma
Disease control CompletedThis phase 2 trial tested a combination of two drugs—anlotinib (a targeted therapy) and toripalimab (an immunotherapy)—in 70 people with advanced soft-tissue sarcoma that had stopped responding to standard treatment. The goal was to see if the combo could shrink tumors or slow di…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental combo shows promise in tough sarcoma
Disease control CompletedThis early-phase trial tested a combination of two drugs—LVGN6051, an experimental immune therapy, and anlotinib, a targeted cancer pill—in 39 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The main goals were to check safety and find…
Phase 1/2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radioactive compound shows promise in targeting Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it…
Early phase 1 • Sponsor: Lanzhou University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Drug-Coated membrane targets sarcoma after surgery
Disease control CompletedThis early-stage trial tested a special membrane loaded with the drug SN-38 in 21 people with recurrent or advanced retroperitoneal sarcoma. The membrane was placed in the surgical area after tumor removal to see if it is safe and tolerable. The goal is to find the right dose and…
Phase 1 • Sponsor: CEBIOTEX • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise in slowing rare sarcoma growth
Disease control CompletedThis study tested whether adding the drug berzosertib to standard chemotherapy (gemcitabine) can help control a rare soft-tissue cancer called leiomyosarcoma. 58 adults with advanced or spreading disease took part. The goal was to see if the combination could stop or shrink tumor…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for rare sarcoma? drug combo tested in 44 patients
Disease control CompletedThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (doxorubicin) could help people with advanced soft tissue sarcoma that has spread or come back. The trial included 44 adults whose cancer could be measured and who were healthy enough for …
Phase 1/2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured ho…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy duo takes on rare sarcoma in new trial
Disease control CompletedThis phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and relatlimab, can help people with advanced or metastatic soft-tissue sarcoma. The study enrolled 68 adults whose tumors had a specific immune structure. Researchers measured how many patients had th…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug cocktail targets tough sarcomas in young patients
Disease control CompletedThis study tested a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, in 59 teenagers and young adults whose sarcoma (a type of bone or soft tissue cancer) had returned or not responded to standard treatment. The main goals were to see if the drug combo could…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cancer drug shows promise in keeping sarcoma in check
Disease control CompletedThis phase 2 trial tested whether the drug regorafenib (Stivarga) could help keep metastatic soft tissue sarcoma from growing after initial chemotherapy. 127 adults whose cancer was stable or shrinking after six cycles of doxorubicin-based chemo were randomly assigned to receive …
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Drug holiday or not? sarcoma study tests best strategy
Disease control CompletedThis study looked at 53 adults with advanced soft tissue sarcoma who had stable disease or improvement after 6 cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delays cancer progression and…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for sarcoma patients: drug slows tumor growth in late-stage trial
Disease control CompletedThis study tested the drug regorafenib in 219 adults with soft tissue sarcoma that had spread and was no longer responding to standard chemotherapy. Participants were randomly assigned to receive either regorafenib or a placebo. The main goal was to see if the drug could delay ca…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Targeted pill shows promise for rare genetic cancers
Disease control CompletedThis study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…
Phase 2 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy for rare sarcoma shows promise in early trial
Disease control CompletedThis early-phase trial tested whether adding a drug called avelumab to radiation therapy is safe for people with advanced soft-tissue sarcoma that has spread. Twelve adults with at least two tumors not curable by standard treatments took part. The main goal was to check for side …
Phase 1/2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a cancer drug boost radiation for rare sarcomas?
Disease control CompletedThis early-phase trial tested whether adding the drug olaparib to standard radiation therapy is safe for people with advanced soft-tissue sarcoma that cannot be removed by surgery. 41 participants received olaparib pills alongside daily radiation for about 7.5 weeks. The main goa…
Phase 1 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immune cells take on sarcoma in early trial
Disease control CompletedThis early-phase trial tested a treatment that uses a patient's own immune cells (called TILs) to fight soft tissue sarcoma. Nine young adults received chemotherapy to prepare their bodies, then an infusion of their own TILs plus high-dose IL-2 to boost the immune response. The m…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental combo shows promise for rare sarcomas
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine) is safe for people with two rare types of soft tissue sarcoma (leiomyosarcoma and undifferentiated pleomorphic sarcoma). Twenty-five adults with advanced or in…
Phase 1/2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control CompletedThis study tested a combination of two chemotherapy drugs—trabectedin and cyclophosphamide—in 50 adults with advanced soft-tissue sarcomas that had already been treated. The goal was to find a safe dose and see if the combo could stop or slow tumor growth. Results showed the trea…
Phase 1/2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase 1/2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy aims to shrink sarcomas before surgery
Disease control CompletedThis study tested whether giving a targeted drug called Apatinib along with radiation therapy before surgery is safe and effective for people with soft tissue sarcoma in the arms, legs, or trunk. 30 adults took part. The main goal was to see how many had major wound problems with…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a pill make radiation work better for sarcoma patients?
Disease control CompletedThis phase 2 trial tested whether adding the drug fluzoparib to standard preoperative radiation therapy improves outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. Fifty-two adults took part, receiving either radiation alone or radiation plus fluzoparib bef…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo shows promise for rare cancers
Disease control CompletedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them fro…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise in Hard-to-Treat sarcomas
Disease control CompletedThis study tested a drug called ADI-PEG 20 combined with two chemotherapy drugs (gemcitabine and docetaxel) in 98 people with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer. The goal was to see if the combination could slow cancer growth better than…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental combo therapy targets hard-to-treat sarcoma
Disease control CompletedThis study tested a two-step treatment for people with advanced soft tissue sarcoma that had stopped responding to standard therapy. First, a drug called LTX-315 was injected into a tumor to attract immune cells. Then, that tumor was removed, and the immune cells were grown in a …
Phase 2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and eribulin, in 30 people with advanced soft tissue sarcomas (liposarcoma or leiomyosarcoma) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or slow their growth. Th…
Phase 1/2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Fewer radiation sessions before sarcoma surgery shows promise in early trial
Disease control CompletedThis pilot study tested a shorter course of radiation (hypofractionated) given before surgery for soft tissue sarcoma of the arm, leg, or chest wall. The goal was to see if this approach is safe, feasible, and controls the tumor locally. Thirty-five adults with localized sarcoma …
Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental combo shrinks sarcomas before surgery?
Disease control CompletedThis early-phase trial tested a drug called navtemadlin given alongside radiation therapy before surgery for soft tissue sarcoma. The goal was to find a safe dose and see if the combination could shrink tumors, making surgery easier. 39 patients with intermediate or high-grade sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested the combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find a safe dose and check for side effects. Researchers also lo…
Phase 1 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 14:10 UTC
-
New cancer drug EVT801 tested in humans for first time
Disease control CompletedThis early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…
Phase 1 • Sponsor: Kazia Therapeutics Limited • Aim: Disease control
Last updated Jun 26, 2026 13:12 UTC
-
New imaging agent targets LRRC15 to sharpen cancer diagnosis
Diagnosis CompletedThis study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
AI reads MRI scans to spot hidden sarcomas
Diagnosis CompletedThis study tested whether artificial intelligence (AI) can help doctors tell the difference between cancerous and non-cancerous soft tissue lumps using MRI scans. 186 patients with soft tissue masses had extra MRI images taken. The AI was trained to identify which lumps were sarc…
Sponsor: The Leeds Teaching Hospitals NHS Trust • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Vitamin d gel on the scalp: a new hope against chemo hair loss?
Symptom relief CompletedThis early-stage trial is testing whether a topical solution containing calcitriol, a form of vitamin D, can safely reduce hair loss in adults receiving taxane-based chemotherapy for breast, gynecologic, or other solid tumors. Participants apply the solution to their scalp twice …
Phase 1 • Sponsor: BPGbio • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Ancient Mind-Body practice tested as fatigue fighter for men after cancer
Symptom relief CompletedThis study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
New app aims to empower cancer survivors with disabilities
Symptom relief CompletedThis study tested a mobile app called WeCanManage designed to help cancer survivors with disabilities manage long-term effects of their illness and treatment. Twenty adults who had breast cancer, head and neck cancer, or sarcoma used the app and reported on how helpful and easy i…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Nurse video visits help cancer patients after hospital discharge
Symptom relief CompletedThis study tested a program called CONTINUUM, where advanced cancer patients had a video visit with an oncology nurse within three days of leaving the hospital. The goal was to help patients feel more confident managing their health and improve communication with their care team.…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Tiny gold seeds could sharpen radiation for spine tumors
Knowledge-focused CompletedThis study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New checklist helps sarcoma patients prepare for life after limb surgery
Knowledge-focused CompletedThis study tested a simple checklist tool to help people with sarcoma think about and plan for their future mobility needs, like getting around the house or dressing. 27 patients and their caregivers used the checklist after limb-saving or amputation surgery. The goal was to see …
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Scientists analyze genetic markers in stored samples to boost personalized medicine
Knowledge-focused CompletedThis study looked at DNA methylation patterns in stored samples from 90 patients with rare skeletal disorders, sarcomas, or inflammatory arthritis. The goal was to better understand these patterns and explore their potential for diagnosis and treatment. The research aimed to impr…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Gene test aims to personalize sarcoma treatment
Knowledge-focused CompletedThis study looked at whether advanced genetic testing (called NGS) can be done quickly enough to help guide treatment choices for people with advanced soft-tissue sarcoma. About 600 adults with this rare cancer took part. The goal was to see if using genetic information to pick t…
Phase 3 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Sarcoma Patients' voices heard: new tool to measure what really matters
Knowledge-focused CompletedThis completed study with 654 sarcoma patients aims to create a better way to measure health-related quality of life. Current questionnaires miss key issues unique to sarcoma, like specific side effects and functional problems. By interviewing patients and healthcare professional…
Sponsor: The Netherlands Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for biomarkers to personalize proton beam cancer therapy
Knowledge-focused CompletedThis completed study enrolled 84 people with brain tumors, meningioma, or high-grade sarcoma who received proton beam therapy. Researchers analyzed tumor and blood samples to find biomarkers that might predict how well the cancer responds to treatment. The goal is to eventually h…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Could a common Anti-Nausea pill change how chemo works?
Knowledge-focused CompletedThis study looked at 59 people with soft tissue sarcoma who were getting chemotherapy with doxorubicin and ifosfamide. Researchers wanted to see if adding the anti-nausea drug aprepitant changed the amount of ifosfamide in the blood. Patients had blood samples taken during their …
Phase 4 • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Study reveals End-of-Life care patterns for sarcoma patients
Knowledge-focused CompletedThis study reviewed medical records of 207 adults who died from sarcoma to understand how they were cared for by palliative teams. Researchers looked at when patients first saw a palliative care doctor, were admitted to a palliative care unit, or received advice from a mobile pal…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Dashboard tool aims to streamline sarcoma care
Knowledge-focused CompletedThis study tested a tool called an oncology dashboard that shows a patient's cancer treatment information to them, their doctor, and their radiologist. The goal was to see if it helps patients understand their disease better and makes care more efficient. The study included 92 pe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists probe why older skin turns cancerous
Knowledge-focused CompletedThis study looks at healthy skin tissue from 58 people with sarcoma to understand how aging changes cells and may increase cancer risk. Researchers compare skin from younger adults (18-40) and older adults (55+) to find markers of aging. The goal is to learn why certain skin canc…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Could a Radiation-Free MRI replace risky scans for kids with cancer?
Knowledge-focused CompletedThis study tested whether a special MRI technique called diffusion-weighted MRI (DWI-MRI) can safely and accurately stage sarcomas in children without using radiation. 98 children with bone or soft-tissue sarcomas received DWI-MRI scans, and researchers compared the results to st…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a smartphone app ease the burden for young cancer survivors?
Knowledge-focused CompletedThis completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Scientists track Body's reaction to cancer immunotherapy
Knowledge-focused CompletedThis study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
PET scans may help guide chemo for rare abdominal cancer
Knowledge-focused CompletedThis study tested whether PET scans can detect early response to chemotherapy in people with retroperitoneal sarcoma, a rare cancer in the abdomen. 18 participants received extra PET scans before and after their first chemo cycle. The goal was to see if PET could predict tumor sh…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
AI analyzes 700 sarcoma cases to unlock survival secrets
Knowledge-focused CompletedResearchers used machine learning to analyze electronic health records from 700 patients with osteosarcoma or Ewing's sarcoma. The goal was to find patterns in survival and other outcomes. No new treatment was tested; instead, the study aimed to learn from existing data to potent…
Sponsor: University of Milano Bicocca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Can we map a Tumor's genes fast enough to help patients?
Knowledge-focused CompletedThis pilot study tested whether advanced genetic sequencing of tumors can be done quickly enough to guide treatment decisions. Researchers took blood and tumor samples from 24 adults with advanced soft-tissue sarcoma or metastatic colorectal cancer. They measured how long it took…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:40 UTC
-
Massive sarcoma study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study looked back at medical records of over 2,100 patients with metastatic soft tissue sarcoma treated in France between 1990 and 2013. Researchers analyzed which treatments patients received, including chemotherapy and local therapies, and how long they lived. The goal is …
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:46 UTC